Patients self-administer dosages of both drugs using a pen-like injector
Semaglutide targets GLP-1 only, while Retatrutide combines GLP-1, GIP and glucagon receptor activity, giving it a broader metabolic signalling profile
[3] Retatrutide triple agonist review, PubMed
La inyeccin subcutnea de Mounjaro (tirzepatida 5 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg y 12.5 mg), solo con receta mdica, no ha sido aprobada por la FDA como segura ni eficaz para tratar la obesidad o el sobrepeso
This is not a sign that the drug has stopped having an effect
Wang, L., Wang, Q., Li, L., Kaelber, D